6/4/2021 9:19:53 AM
Alkermes Reports New Data From Its ARTISTRY Clinical Development Program For Nemvaleukin Alfa
6/1/2021 7:04:44 AM
Alkermes Announces FDA Approval Of LYBALVI For Schizophrenia And Bipolar I Disorder
5/20/2021 7:01:18 AM
Alkermes Appoints Emily Peterson Alva To Board
5/13/2021 7:02:46 AM
Alkermes To Begin Accepting Applications For Alkermes Inspiration Grants Program Beginning On May 20
5/3/2021 7:08:14 AM
Alkermes To Present Clinical Data And Outcomes Research From Psychiatry Portfolio During Mental Health Awareness In May
4/30/2021 7:02:19 AM
Alkermes Enters Agreement With Sarissa Capital; Grants Sarissa Right To Designate Director To Board
4/28/2021 7:11:50 AM
Alkermes Says Two Abstracts Accepted For Presentation At 2021 American Society Of Clinical Oncology Annual Meeting
4/28/2021 7:06:19 AM
Alkermes Plc Q1 GAAP Loss Per Share $0.14 And Non-GAAP EPS Of $0.11
4/27/2021 7:08:56 AM
Alkermes Announces Initiation Of ARTISTRY-6 Phase 2 Trial
4/7/2021 7:07:14 AM
Alkermes Enters Clinical Trial Collaboration And Supply Agreement With Merck
3/25/2021 7:07:27 AM
Alkermes Plans To Provide New Updates And Disclose New Programs In Neuroscience And Oncology Development Pipeline
3/11/2021 7:01:48 AM
Alkermes Announces FDA Grants Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma
2/11/2021 7:02:04 AM
Alkermes Plc Q4 Loss Per Share $0.27; Non-GAAP EPS $0.10